Product
SPN-810
Aliases
SPN-810 (18 mg), SPN-810 (36 mg)
4 clinical trials
1 indication
Indication
ADHDClinical trial
Assessment of the Efficacy and Safety of Molindone Hydrochloride Extended-Release for the Treatment of Impulsive Aggression in Pediatric Patients With Attention Deficit/Hyperactivity Disorder in Conjunction With Standard ADHD TreatmentStatus: Completed, Estimated PCD: 2019-09-04
Clinical trial
Assessment of the Efficacy and Safety of Molindone Hydrochloride Extended-Release for the Treatment of Impulsive Aggression in Pediatric Patients With Attention Deficit/Hyperactivity Disorder in Conjunction With Standard ADHD TreatmentStatus: Completed, Estimated PCD: 2019-11-15
Clinical trial
Open-Label Extension Study to Evaluate the Long-Term Safety of Molindone Hydrochloride Extended-Release Tablets for the Treatment of Impulsive Aggression in Pediatric and Adolescent Subjects With Attention Deficit/Hyperactivity Disorder (ADHD) in Conjunction With Standard ADHD TreatmentStatus: Terminated, Estimated PCD: 2021-05-01
Clinical trial
Assessment of Efficacy and Safety of SPN-810 for the Treatment of Impulsive Aggression (IA) in Adolescent Subjects With Attention Deficit/Hyperactivity Disorder (ADHD) in Conjunction With Standard ADHD TreatmentStatus: Terminated, Estimated PCD: 2020-01-22